Humacyte, Inc. (HUMA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $812.50M; Retained Earnings (Accumulated Deficit)USD $-781.27M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $23.00K; Additional Paid in CapitalUSD $756.07M; Retained Earnings (Accumulated Deficit)USD $-744.47M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $20.00K; Additional Paid in CapitalUSD $729.94M; Retained Earnings (Accumulated Deficit)USD $-726.85M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $697.28M; Retained Earnings (Accumulated Deficit)USD $-702.04M.
Humacyte, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $28.00K | $812.50M | $-781.27M | $31.26M | 3 month · $2.61M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $23.00K | $756.07M | $-744.47M | $11.62M | 3 month · $3.17M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $20.00K | $729.94M | $-726.85M | $3.11M | 12 month · $10.41M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $16.00K | $697.28M | $-702.04M | $-4.75M | 3 month · $2.51M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $16.00K | $688.57M | $-684.53M | $4.05M | 3 month · $2.43M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $16.00K | $682.90M | $-646.88M | $36.04M | 3 month · $2.49M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $13.00K | $633.33M | $-686.01M | $-52.67M | 12 month · $6.14M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $12.00K | $601.34M | $-665.08M | $-63.72M | 3 month · $1.55M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $12.00K | $597.57M | $-625.87M | $-28.29M | 3 month · $1.44M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $12.00K | $595.35M | $-569.21M | $26.15M | 3 month · $1.45M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $10.00K | $550.85M | $-537.31M | $13.55M | 12 month · $6.83M | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $10.00K | $549.19M | $-512.21M | $36.99M | 3 month · $1.77M | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $10.00K | $547.32M | $-486.21M | $61.12M | 3 month · $1.84M | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $10.00K | $545.38M | $-463.51M | $81.89M | 3 month · $1.81M | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $10.00K | $543.46M | $-426.54M | $116.93M | 12 month · $6.18M | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $10.00K | $541.48M | $-422.82M | $118.67M | 3 month · $1.48M | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $10.00K | $539.79M | $-397.54M | $142.26M | 3 month · $1.49M | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $10.00K | $538.28M | $-434.40M | $103.89M | 3 month · $1.55M | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $10.00K | $536.74M | $-414.57M | $122.17M | 12 month · $10.15M | (m) | (m) | 12 month · $13.91M |
| 2021-09-30 | (m) | $10.00K | $533.01M | $-457.16M | $75.86M | 3 month · $1.88M | $75.86M | (m) | 3 month · $13.91M |
| 2021-08-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.90M | $100.00K |
| 2021-06-30 | (m) | (m) | $12.73M | $-7.73M | $-379.76M | 3 month · $2.93M | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $13.02M | $-8.02M | $-365.52M | 3 month · $2.53M | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $1.00K | $37.78M | $-388.10M | $-350.32M | 12 month · $4.69M | $-350.32M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $5.04M | $-40.95K | $-335.40M | 3 month · $1.17M | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-318.82M | 3 month · $1.11M | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-305.11M | 3 month · $1.18M | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-288.79M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |